UNION KOREA PHARM Extends Trading Suspension Period Due to Capital Reduction and Delisting Risk

KOSDAQ Market Division changed the trading suspension period for UNION KOREA PHARM.
Reason for change is 'investor protection', related to capital reduction and delisting process.
Original suspension period: April 7, 2026 ~ until court decision on preliminary injunction to suspend delisting.
Changed suspension period: April 7, 2026 ~ (1) until court decision on injunction, or (2) if change of listing application completed within 1 month of capital reduction event, until new shares listing; if not completed, until day before delisting.
This indicates UNION KOREA PHARM faces capital reduction and delisting risk, exposing existing shareholders to equity value decline and potential delisting.